Advertisement

Topics

Baml initiate coverage of Zogenix, Inc. $ZGNX) with a Buy rating and $63 PO. ZGNX is a clinical-stage biotech company that develops treatment for pediatric epilepsies with focus on Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

20:08 EDT 14 Sep 2018 | tgtxdough

Baml initiate coverage of Zogenix, Inc. ) with a Buy rating and $63 PO. ZGNX is a clinical-stage biotech company that develops treatment for pediatric epilepsies with focus on Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

Original Article: Baml initiate coverage of Zogenix, Inc. $ZGNX) with a Buy rating and $63 PO. ZGNX is a clinical-stage biotech company that develops treatment for pediatric epilepsies with focus on Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

NEXT ARTICLE

More From BioPortfolio on "Baml initiate coverage of Zogenix, Inc. $ZGNX) with a Buy rating and $63 PO. ZGNX is a clinical-stage biotech company that develops treatment for pediatric epilepsies with focus on Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS)."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...